Increased Dihydroceramide/ceramide ratio mediated by defective expression of degs1 impairs adipocyte differentiation and function by Barbarroja, Nuria et al.
  
 
 
 
 
Increased dihydroceramide/ceramide ratio mediated by 
defective expression of degs1 impairs adipocyte 
differentiation and function. 
 
 
Journal: Diabetes 
Manuscript ID: DB14-0359.R2 
Manuscript Type: Original Article 
Date Submitted by the Author: n/a 
Complete List of Authors: Barbarroja, Nuria; University of Cambridge, Wellcome Trust MRC Institute 
of Metabolic Science 
Rodriguez-Cuenca, Sergio; University of Cambridge, Wellcome Trust MRC 
Institute of Metabolic Science 
Nygren, Heli; VTT Technical Research Centre of Finland,  
Camargo, Antonio; Reina Sofia University Hospital, 4Lipids and 
Atherosclerosis Research Unit, IMIBIC 
Pirraco, Ana; University of Porto, Department of Biochemistry (U38-FCT), 
Faculty of Medicine 
Relat, Joana; Universitat de Barcelona, Departament de BioquímicaiBiologia 
Molecular 
Cuadrado, Irene; Universidad Complutense de Madrid, Departamento de 
Farmacología 
Pellegrinelli, Vanessa; University of Cambridge, Wellcome Trust MRC 
Institute of Metabolic Science 
Medina-Gomez, Gema; Universidad Rey Juan Carlos, Departamento de 
Bioquímica, Fisiología y Genética Molecular 
Lopez-Pedrera, Chary; Reina Sofia University Hospital, IMIBIC 
Tinahones, Francisco; Instituto de Salud Carlos III, Spain and Hospital 
Virgen de la Victoria, CIBER in Physiopathology of Obesity and Nutrition 
(CB06/03) 
Symons, David; University of Utah, Division of Endocrinology, Metabolism, 
and Diabetes 
Summers, Scott; Duke-National University of Singapore Graduate Medical 
School, Program in Cardiovascular and Metabolic Disorders 
Oresic, Matej; VTT Technical Research Centre of Finland,  
Vidal-Puig, Antonio; University of Cambridge, Clinical Biochemistry 
  
 
 
For Peer Review Only
Diabetes
 1
Increased dihydroceramide/ceramide ratio mediated by defective expression of 
degs1 impairs adipocyte differentiation and function. 
 
Nuria Barbarroja
1,2
*, Sergio Rodriguez-Cuenca
1
*, Heli Nygren
3
,Antonio 
Camargo
1,4
,Ana Pirraco
1,5
,Joana Relat
6
, Irene Cuadrado
7
, Vanessa Pellegrinelli
1
, Gema 
Medina-Gomez
1,13
,Chary Lopez-Pedrera
2
,Francisco J. Tinahones
8
,J. David Symons
9,10
, 
Scott A. Summers
11
,Matej Oresic
4,12
and Antonio Vidal-Puig
1,14
 
 
*These two authors contributed equally to this work 
1
Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's 
Hospital, University of Cambridge. Cambridge, UK. 
2
IMIBIC, Reina Sofia University Hospital, Cordoba, Spain. 
3
VTT Technical Research Centre of Finland, Espoo, Finland. 
4Lipids and Atherosclerosis Research Unit, IMIBIC/Reina Sofia University Hospital, Spain. 
5
Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, Portugal. 
6Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, 08028 Spain. 
7
Departamento de Farmacología, Universidad Complutense de Madrid, Spain. 
8
CIBER in Physiopathology of Obesity and Nutrition (CB06/03), Instituto de Salud Carlos III, Spain and 
Hospital Virgen de la Victoria, Malaga, Spain (IBIMA). 
9
College of Health, University of Utah, Salt Lake City, Utah.  
10
Division of Endocrinology, Metabolism, and Diabetes, University of Utah, Salt Lake City, Utah. 
11Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Graduate 
Medical School, Singapore 169857 
12
Institute for Molecular Medicine Finland, Helsinki, Finland.  
13Currently in Departamento de Bioquímica, Fisiología y Genética Molecular, Universidad Rey Juan 
Carlos, Spain. 
14
Wellcome Trust Sanger Institute, Hinxton, UK 
Corresponding authors e-mail: 
nuria.barbarroja.exts@juntadeandalucia.es;sr441@medschl.cam.ac.uk;ajv22@medschl.cam.ac.uk 
Address reprint request to: Professor Antonio Vidal-Puig, Level 4, Institute of Metabolic Science, Box 
289, Addenbrooke’s Hospital, Cambridge, CB2 0QQ  
Tel: 44-(0)1223762790 Fax: 44-(0)1223330598  
RUNNING TITLE: DEGS1downregulation impairs adipocyte function. 
Word count: 3997 
Number of tables and figures: 7 figures and 1 table 
 
 
Page 1 of 67
For Peer Review Only
Diabetes
 2
ABSTRACT 
Adipose tissue dysfunction is an important determinant of obesity-associated lipid 
induced metabolic complications. Ceramides are well known mediators of lipid induced 
insulin resistance in peripheral organs such as muscle. DEGS1 is the desaturase 
catalysing the last step in the main ceramide biosynthetic pathway. Functional 
suppression of DEGS1 activity results in substantial changes in ceramide species likely 
to affect fundamental biological functions such as oxidative stress, cell survival and 
proliferation. Here, we show that degs1 expression is specifically decreased in the 
adipose tissue of obese patients and murine models of genetic and nutritional obesity. 
Moreover, loss of function experiments using pharmacological or genetic ablation of 
DEGS1 in preadipocytes prevented adipogenesis and decreased lipid accumulation. 
This was associated with elevated oxidative stress, cellular death and blockage of the 
cell cycle. These effects were coupled with increased dihydroceramide content.  
Finally, we validate in vivo that pharmacological inhibition of DEGS1 impairs 
adipocyte differentiation. These data identify DEGS1 as a new potential target to restore 
adipose tissue function and prevent obesity-associated metabolic disturbances. 
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Dysfunction of white adipose tissue (WAT) and impaired differentiation of new 
adipocytes may lead to lipid leakage and inappropriate accumulation of ectopic lipids in 
peripheral organs, causing lipotoxicity and the Metabolic Syndrome(1). The toxic 
effects of lipids are determined by both the quantity and also by their qualitative 
characteristics(2). Whereas it is well documented that specific species of sphingolipids 
and ceramides mediate lipotoxicity in liver and muscle(3; 4), the contribution of specific 
lipotoxic species to WAT dysfunction in the context of obesity is still not well defined. 
It is known that in rodent WAT, ceramides increase in response to HFD(5; 6) 
concomitantly with the onset of insulin resistance(6). Lipid analysis of WAT from 
human obese subjects has produced conflicting results, showing either increased or 
decreased ceramide levels in obese and insulin resistant patients(7; 8). 
Ceramides can be synthesised from sphingomyelins, but the main contributor to their 
biosynthesis is the de novo pathway. The final reaction of the de novo pathway is 
catalyzed by a ∆4-dihydroceramide desaturase (DEGS1) that adds a 4,5-trans-double 
bound on the sphingoid base of the dihydroceramide (DhCer) (9). The other enzyme, 
DEGS2 catalyzes the synthesis of phytoceramides(10), whose expression is restricted to 
skin, intestine and kidney. 
There is evidence that downregulation of degs1 increases the DhCer/Cer ratio in 
different cellular models. Although DhCer was considered an inactive precursor of 
ceramides(11), recent studies have suggested their relevance as modulators of cell cycle, 
apoptosis, autophagy or oxidative stress(12; 13), processes that a priori are expected to 
compromise the development and function of adipose tissue. 
Since DEGS1 is the key enzyme regulating the DhCer/Cer ratio, understanding its 
regulation is important in determining the pathophysiological relevance of this pathway 
in adipose tissue. Of note, degs1 has recently been identified in a GWAS study as a 
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candidate gene associated with fat mass accumulation in mice(14) further suggesting 
that DEGS1 may be relevant for the adaptive accretion of adipose tissue. Moreover, 
DEGS1 could be considered an attractive therapeutic target for obesity-associated 
insulin resistance, since Fenretinide has been claimed to improve insulin sensitivity by 
inhibiting DEGS1(15), although other molecular targets cannot be ruled out.  
Here we show that DEGS1 expression is selectively perturbed in the WAT of murine 
models of nutritional and genetically induced obesity and in WAT of morbidly obese 
patients. In vitro analysis revealed that both pharmacological inhibition and genetic 
ablation of DEGS1 results in impaired adipocyte differentiation and lipid accumulation, 
effects mediated by increased dihydroceramide content. In vivo, pharmacological 
inhibition of DEGS1 also resulted in impaired adipocyte differentiation. Decreased 
levels of DEGS1 were associated with increased oxidative stress, accelerated cellular 
death and blockage of cell cycle. We also show data supporting that DEGS1 expression 
is regulated by PPARγ.  
RESEARCH DESIGN AND METHODS 
Mice husbandry 
Animals were housed at 22-24°C with 12h light/dark cycles. Food and water were 
available ad libitum. Lean wildtype, PPARγ2
−/−
 and PPARγ2
−/−
xob/ob mice (POKO) 
(16) were used for profiling purposes. Mice were placed on a normal chow diet 
(D12450B) or in HFD (D12451) from Research Diets. 
For the pharmacological inhibition of DEGS1, 10 weeks-old male C57BL/6 WT mice 
were used.  Mice were given a HFD for 5weeks before C8-CPPC (Matreya) 
administration. All protocols used were approved by the UK Home Office. 
Intraperitoneal injection of cyclopropenylceramide.  
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Mice were distributed in 2 groups (n=8) and administered daily vehicle (2-
hydroxypropyl betacyclodextrine) or C8-CPPC (2mg/kg/day) for 9d via intraperitoneal 
injection. Mice were culled at the end of the experiment and WAT| was removed for 
gene expression and microscopy analysis. No differences in food intake, lean mass 
and fat content were observed during the treatment. 
Ex vivo experiments in isolated mature adipocytes 
Adipocytes from gonadal WAT of 16weeks C57BL/6 mice were obtained by 
collagenase type II digestion at 37ºC. After digestion, adipocytes were placed in DMEM 
media with or without 1µM C8-CPPC every 5h for a total period of 20h. 
Retroviral Short Hairpin RNA Constructs for DEGS1 
A RNAi-Ready pSIREN-RetroQ vectors (BD Biosciences) were used to target degs1 in 
3T3L1-cells. Sequences targeting degs1 were ligated into the pSIREN vector as 
described in manufacturer’s instructions. Retroviruses were generated by transfecting 
BOSC cells (ATCC) with the pSIREN plasmids using FuGene6 (Roche). Supernatant 
with the viral content was used to transfect 3T3-L1 preadipocytes. 24h after retroviral 
infection, the cells were selected with puromycin (4µg/ml).  
Culture, differentiation and treatment of 3T3-L1 preadipocytes 
Cells were differentiated into adipocytes (day9) accordingly to the protocol described in 
(17) with or without rosiglitazone 0.1µM. Lipid accumulation was assessed by Oil red 
O solution(18). 
Pharmacological inhibition of DEGS1 activity in vitro. 
Effects on differentiation. At day 0 of differentiation, 3T3-L1 cells were treated with 
C8-CPPC 1µM and/or Rosiglitazone 0.1µM for 96h.  
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Effects on lipolysis.On day 8 of differentiation, after 48h treatment with C8-CPPC 1µM 
the cells were exposed to Noradrenaline (NA) (10
−8
 M and 10
−7
 M) for 6h. 
Effects on insulin signalling. On day 8 of differentiation, after 48h treatment with C8-
CPPC 1µM the cells were exposed to insulin (10nM and 100nM) for 15min.  
Effects on glut4, adiponectin. On day 8 of differentiation, after 48h treatment with C8-
CPPC 0.5-1µM the cells were exposed to insulin.  
Effects on AMPK. On day 8 of differentiation, after 48h treatment with C8-CPPC 0.5-
1µM the cells were exposed to insulin (10nM and 100nM), rosiglitazone (1nM and 
10nM) and metformin (100nM) for 24h.  
Dihydroceramide treatment.  
3T3-L1 preadipocytes were treated at day 0 of differentiation with the induction cocktail 
and C2DhCer at 50µM for 3d, and a second batch of cells were exposed at day 3 of 
differentiation and treated with C2DhCer at 50µM for 3d. All batches were taken until 
final differentiation at day 9. 
Human samples 
The cohort included 28 morbidly obese (MO) and 6 non-obese subjects with no 
alterations to lipid or glucose metabolism, as controls (Table I). Approval for the study 
was given by the ethics committee and all patients gave their informed consent. Visceral 
adipose tissue biopsies were obtained from MO patients undergoing bariatric surgery 
(Scopinaro procedure) or laparoscopic surgery (hiatus hernia repair or 
cholecystectomies) for the lean subjects. 
 
 
Western blotting 
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Protein extracts were prepared using the Nuclear and Cytoplasmic Extraction Reagents 
Kit (Pierce) according to manufacturer’s instructions. Immunoblots were incubated with 
the following antibodies: PPARγ, C/EBPβ, CyclinA, (Santa Cruz) CyclinB1, D1, D3 
and E1,cdk4, AKT, Ser473-pAKT, p44/42 MAPK, phospho-p44/42 MAPK, Ser660-
pHSL, Ser565-pHSL, total HSL, ATGL, caveolin-1, plin1, glut4, adiponectin, and 
AMPK (Cell Signalling), adfp/adrp and abhd5 and anti-β-Actin (Abcam).  
RT-PCR 
RNA was extracted using TRI Reagent (Sigma) and reverse-transcribed to cDNA. Real-
Time PCR using SYBRgreen was performed according to manufacturer’s instructions 
(ABI). Primer sequences were obtained from Primer Blast(19). Expression of genes was 
corrected by the geometrical average of 18s, β2m, β-act, and 36b4 using Bestkeeper 
(20).  
Apoptosis: combined Annexin-V/propidium iodide staining 
Viability was assessed by using an Annexin-V/propidium iodide kit (Bender 
MedSystems), according to manufacturer's recommendations. Binding of fluorescein-
conjugated Annexin-V and propidium iodide was measured by FACSCalibur(BD). 
Cellular proliferation:  
Cell viability was assessed using an XTT colorimetric assay (Roche) following the 
protocol supplied by the manufacturer. Cell proliferation was analyzed by quantification 
of the incorporation of bromodeoxyuridine (Roche). 
Bodipy staining, Reactive Oxygen Stress (ROS) production and mitochondrial 
content. 
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Cells were incubated with Bodipy at 4ºC or alternatively with 20µM DCF-DA or 
100nM Mitotracker (Invitrogen) at 37°C for 30 min and analysed on a FACSCalibur. 
Cellular oxygen consumption 
Cells were exposed to oligomycin (1µM), C8-CPPC (0.9µM) and Antimycin/Rotenone 
(1µM each); O2 consumption was measured using the XF24 analyzer (Seahorse 
Bioscience) for a period of 90min. 
 
Whole-mount confocal microscopy 
Gonadal adipose tissue was fixed in 4% paraformaldehyde. Samples were incubated at 
4°C with mouse pref-1 or rabbit Ki67 primary antibodies. Nuclei and neutral lipids were 
stained with Hoechst 33342, and BODIPY 493/503 respectively. Sample examination 
was performed using a Zeiss 510 confocal laser scanning microscope (Carl Zeiss). 
Pref1, Ki67, Bodipy positive cells and total cells (up to 913 cells/field) were 
automatically counted by using Image J software in 3 independent fields in each tissue. 
Light microscopy analysis  
Samples for adipose tissue H&E staining were prepared as described elsewhere (16). 
Adipocyte sizes were measured using Cell P (Olympus soft Imaging Solutions GMBH).  
Between 1000-3000 adipocytes from each mouse were used to obtain the mean cell-
area. 
 
 
Luciferase reporter assay 
HEK293 cells were transfected using Lipofectamine LTX (Invitrogen), following the 
manufacturer's instructions. 75ng of the reporter plasmid (3xPPRE TKLuc) and 37.5ng 
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of the eukaryotic expression vector (pSV-PPARγ) were cotransfected to each well. The 
plasmid pRL-CMV (5ng/well) was included as an internal control. 24h post transfection 
cells were treated as indicated (DMSO, Rosiglitazone 10µM, GW1929 10µM, C2 and 
C16 DhCers and Cer 100 µM). Luciferase assays were performed using the dual 
luciferase reporter assay system (Promega).  
Lipidomics 
Cells were mixed with 0.9% NaCl and sonicated for 5 min at 5 ºC, 40 kHz. Samples 
were spiked with internal standard (IS). The samples were extracted with 
chloroform:methanol (2:1). The lower phase was collected and mixed with the labeled 
standard mixture (three stable isotope-labeled reference compounds). Lipid extracts 
were analyzed on a Q-ToF Premier mass spectrometer (Waters) combined with an 
Acquity Ultra Performance Liquid chromatography(UPLC/MS). The data was 
processed using MZmine software. The lipids were quantified by normalizing with 
corresponding IS.  
Statistical analysis 
Student t-test (unpaired), ANOVA and Duncan test were used for the statistical 
analysis. Statistically significance was set at p<0.05 and p<0.01. Spearman correlation 
was calculated to estimate the linear correlations between variables p<0.01. 
 
 
RESULTS 
DEGS 1 is downregulated in WAT in obese murine models. 
Tissue distribution analysis showed that degs1 is present in most tissues and it is 
particularly highly expressed in adipose tissue, liver and muscle, whereas degs2 mRNA 
is only detected in intestine (Fig. 1A). Degs1 expression in vivo was positively 
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correlated with WAT mass in lean healthy mice (Fig. 1B). However, this correlation 
was disrupted in murine models of nutritional and genetically induced obesity (HFD 
and ob/ob), where degs1 mRNA expression was decreased vs. controls (Fig.1C and 1F). 
Of note, the dysregulation of degs1 in obesity was limited to WAT, as its expression in 
liver or skeletal muscle was not affected in either HFD fed mice (Fig.1D and 1E) or in 
ob/ob mice (Fig.1G and H). DEGS1 was preferentially expressed in matured adipocytes 
vs. stromal vascular fraction (svf) in lean and ob/ob mice (Fig.S1) and downregulated 
in ob/ob adipocytes vs lean adipocytes. Moreover, this downregulation of degs1 in 
total WAT of HFD fed and ob/ob mice was also recapitulated in visceral AT of 
morbidly obese patients (Fig S2A). 
To determine whether the decrease in degs1 expression was part of a global adaptation 
of de novo ceramide synthesis pathway in obesity, the expression of other genes in this 
pathway were measured. Expression of the sptlc1 and sptlc2 subunits were not changed 
in human visceral AT, nor in ob/ob WAT, but sptlc2 expression was increased in HFD 
WAT (Fig S2B-C). Moreover, both HFD and ob/ob mouse WAT exhibited a reduction 
in a subset of ceramide synthases, suggests a possible defect in the synthesis of specific  
subset of ceramides.  
We then confirmed that modulators of obesity associated inflammation may contribute 
to the downregulation of degs1, as treatment of 3T3-L1 adipocytes with TNFα (5 ng/ml 
and 10ng/ml) for 48h resulted in a dose dependent downregulation of degs1 mRNA 
expression (38.8±3.6% and 45.7±7.3%  reduction respectively).  
We then investigated a link between DEGS1 and the adipogenic programme. It is 
known that obese and insulin resistant murine models and humans have reduced 
expression of pparγ2 in WAT. Furthermore we observed that expression of pparγ2 and 
degs1 were directly correlated in 3T3-L1 after treatment with Rosiglitazone (Fig.S3A). 
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To validate this in vivo, we analyzed the regulation of degs1 in adipose tissue, liver and 
skeletal muscle of pparγ2KO and the POKO mice(16). WAT of pparγ2KO and POKO 
mice expressed significantly lower degs1mRNA levels vs. wt (Fig.S3B). This 
association was restricted to WAT since the expression of degs1 in other metabolic 
organs such as skeletal muscle or liver was not affected when pparγ2 was absent 
(Fig.S3C and D). 
 
DEGS1 controls important cellular functions such as proliferation, survival and 
oxidative stress in 3T3-L1 adipocytes. 
A stable degs1 knock-down 3T3-L1 cell line (65%) (Fig.2A) resulted in inhibition of 
cell growth after 24h (Fig.2B-C). Degs1 knock-down also induced cell death (13.7%) 
and apoptosis (6.3%)(Fig.2E). These were associated with a decrease in cyclin-A and 
cdk2 in degs1KD proliferating cells (Fig.2F) as well as elevated Bax and caspase-
3mRNA (Fig.2D). Elevated reactive oxygen species (ROS) production (Fig.2I) along 
with an upregulation of the expression of antioxidant genes was observed in 
degs1KD preadipocytes (Fig.2H). This was accompanied by impaired mitochondrial 
oxygen consumption (Fig.2G) without changes in the number of mitochondria (Fig.2J).  
 
DEGS1 is required for adipocyte differentiation. 
Expression of degs1 is increased during normal differentiation of 3T3-L1 adipocytes 
(Fig.3A). To investigate whether ablation of DEGS1 affected adipogenesis, 3T3-L1 
degs1KD cells were induced to differentiate. At d9, degs1KD cells showed impaired 
lipid accumulation vs. controls (Fig.3B). Moreover, pref1 mRNA expression, a marker 
for preadipocytes was not decreased in degs1KD cells at d9 suggesting that a relevant 
number of cells remained in the preadipocyte stage (Fig.3C). In addition, expression of 
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proadipogenic and lipogenic genes were downregulated (Fig.3D). Interestingly, 
treatment with rosiglitazone only partially improved the differentiation and lipid 
accumulation rates of degs1KD cells (Fig. S4A-B).  
We tested whether DEGS1 expression may affect the mitotic clonal expansion (MCE).  
In degs1KD cells, pparγ and cebpβ were downregulated compared to controls at time 0 
and 24h following differentiation induction (Fig. S5AB). The expression of PPARγ and 
several cyclins involved in adipogenesis were measured at earlier time points. We noted 
a strong effect of degs1 depletion on PPARγ2 mRNA from time 0. Additionally,   
reduced levels of degs1 blocked MCE as indicated by the inhibition of cyclin D1 and 
cdk2 expression between time 0 and 4h hours after the induction (Fig. S5AB). Cyclin E 
and cyclin D3 expression was also inhibited but at later time points. 
 
 
 
Pharmacological inhibition of DEGS1 recapitulates DEGS1KD antiadipogenic 
phenotype. 
Use of C8-cyclopropenylceramide (C8-CPPC), a selective inhibitor of DEGS1(21) 
further confirmed the relevance of DEGS1 in adipogenesis. Similarly to degs1KD 
cells, 3T3-L1 cells were induced to differentiate and treated simultaneously with C8-
CPPC from time 0h every 6h for 48h. C8-CPPC decreased the expression of 
proadipogenic transcription factors such as PPARγ and C/EBPβ as well as lipogenic 
genes (Fig. 4AC). The antiadipogenic effect of C8-CPPC persisted after Rosiglitazone 
treatment (Fig. 4AC). As expected, analysis of neutral lipids showed that 3T3-L1 cells 
treated with C8-CPPC for 96h accumulated significantly less lipids compared to 
untreated cells (Fig. 4D).  
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Pharmacological inhibition of DEGS1 also impairs adipocyte differentiation in 
vivo. We administered C8-CPPC IP to mice fed a HFD for 5weeks, an experimental 
protocol known to trigger adipocyte hyperplasia. Molecular analysis of the WAT from 
mice treated with C8-CPPC presented higher levels of pref-1+ cells, suggesting an 
increase in the number of preadipocytes vs. controls. Interestingly, a significant number 
of preadipocytes showed evidence of increased proliferation (Ki67+) whereas the 
number of differentiating preadipocytes (pref1+, bodipy +) was significantly smaller in 
comparison to controls (Fig.5A).  These data were reinforced at mRNA level by 
showing increased expression of pref-1 and gata2 (Fig 5B) and the presence of less 
smaller adipocytes in treated mice (Fig.S6). Altogether, these data suggest C8-CPPC 
mediated inhibition of DEGS1 impaired the capacity of preadipocytes to differentiate 
into adipocytes in vivo. 
 
DEGS1 is required for lipid accumulation, basal lipolysis and glucose uptake in 
mature adipocytes. 
We next focused on the effects of DEGS1 inhibition in fully differentiated adipocytes 
by treating isolated mature adipocytes-from the gonadal adipose tissue of C57BL/6 
mice- with C8-CPPC for 24h. C8-CPPC caused a decrease in the expression of lipid 
metabolism genes as well as an increase in antioxidant genes (Fig S7) recapitulating our 
observations in 3T3L1 preadipocytes. 
 
We further investigated the effects of inhibiting DEGS1 on lipolytic activity and insulin 
signalling, and measured adiponectin expression as a representative fingerprint of global 
adipocyte homeostasis in mature differentiated 3T3L1 adipocytes. Thus, we observed 
that basal lipolytic activity was decreased in mature differentiated 3T3L1 adipocytes 
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when treated with C8-CPPC in non-stimulated conditions (Fig. 6A). Systematic 
evaluation of the lipolytic axis showed that under basal conditions, phosphorylation of 
Ser565 was also substantially increased by C8-CPPC concomitantly with a minor 
downregulation of Ser660 phosphorylation (Fig.6B-D) suggesting a decreased HSL 
activity. Moreover, total levels of HSL were also decreased in C8-CPPC treated 
cells. These data suggest that pharmacological inhibition of DEGS1 in mature 
adipocytes disrupts the lipolytic response under non-stimulated conditions a defect that 
was superseded in the presence of NA.  
 
Finally we characterised the effects of pharmacological inhibition of DEGS1 on insulin 
signalling in 3T3-L1 mature adipocytes treated with C8-CPPC for 48h as described 
above, and subsequently incubated in the presence of increasing doses of insulin. No 
major differences where observed in the phosphorylation of AKT in C8-CPPC treated 
cells after acute insulin stimulation (Fig.6E). However, we found that Glut4 protein 
levels were increased in C8-CPPC treated cells, suggesting that glucose uptake may be 
increased (Fig.6F). Interestingly, we also did not observe any differences in either 
adiponectin levels in response to C8-CPPC or in AMPK phosphorylation, a known 
inducer of adiponectin, although increased levels of tAMPK were observed (Fig 6GH). 
 
Both, Pharmacological and Genetic inhibition of DEGS1 increases 
dihydroceramide/ceramide ratio in 3T3-L1-cells. 
 
We confirmed that C8-CPPC increased the DhCer/Cer ratio in 3T3L-1 preadipocytes 
upon inhibition of DEGS1 (Fig.4E). Similarly, degs1KD preadipocytes (d0) exhibited 
an increased DhCer/Cer ratio vs. controls. Downregulation of degs1 expression in 
degs1KD cells was accompanied by a dowregulation of serine palmitoyltransferase 
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(sptlc1) and Ceramide synthase 6 (Cers6), suggestive of a homeostatic readjustment of 
the biosynthetic pathway to compensate for the dysfunction of degs1. Other genes 
related to ceramide homeostasis such as neutral ceramidase (ncdase), and 
glycosylceramide synthase (gcs) were  also downregulated. 
Curiously, at d9, degs1KD cells, despite impaired differentiation, showed a complete 
restoration of the DhCer/Cer ratio (indicated by the normalization of the ceramide pool) 
(Fig.S8A). This could be partially explained by a compensation mechanism, mediated 
by downregulation of neutral ceramidases and the conversion of sphyngomyelins to 
ceramides (upregulation of sphyngomyelinase 2) (Fig.S8B).  
 
The Impairment of adipocyte differentiation during early adipogenesis by DEGS1 
inhibition is recapitulated by Dihydroceramides per se.  
We finally sought to validate whether DhCer by itself could mediate the effects of 
DEGS1 inhibition on adipocyte differentiation in our models of genetic or 
pharmacological inhibition of degs1. 3T3-L1cells were treated with C2-DhCer during a) 
the MCE at time 0 and b) at day 3 after differentiation. DhCer inhibited lipid 
accumulation (Fig.7A) and the expression of genes involved during the early stages of 
adipogenesis (Fig. 7B).  
Since synthetic sphingolipid analogues are known to modulate PPARs activity(22), we 
investigated whether both C2 and C16 DhCer could exert a repressive effect on PPARγ 
activation in the presence of the PPARγ ligands (Fig. 7C). Our results show that DhCer 
can also block the ligand-mediated transactivation of PPARγ. Similar results were 
obtained with ceramides, indicating these effects were not a consequence of the 
unsaturation of the sphingoid moiety (data not shown). 
DISCUSSION 
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The DhCer/Cer ratio has an important homeostatic regulatory role in the cell, 
contributing to cell survival, autophagy and oxidative stress(12; 13). Here we identify 
DEGS1 as an essential metabolic enzyme which is dysregulated in obese states and 
contributes to adipose tissue dysfunction. Our complementary in vitro and in vivo 
approaches reveal that reduced DEGS1 function impairs adipogenesis and lipogenesis 
programmes and increases oxidative stress.  
DEGS1 is expressed in WAT and correlates in rodents with fat mass in healthy states, 
an association that is disrupted in severe forms of obesity. Expression of DEGS1 in liver 
or muscle is not affected by obesity, further indicating that the WAT is particularly 
susceptible to changes in ceramide metabolism in obese states. The relevance to human 
obesity is confirmed by the downregulation of DEGS1 in the adipose tissue of morbidly 
obese patients, and by recent reports showing that DhCer rather than Cer content 
positively correlates with BMI and waist circumference in cohorts of overweight-obese 
subjects(23; 24). To date, only a single functional mutation in the Degs1gene has been 
reported in humans  where patients demonstrate increased serum DhCer and 
decreased cholesterol esters, and decreased waist to hip ratio(25). Globally considered, 
these data suggest the existence of an association between DEGS1 function and fat 
mass. 
The molecular mechanism leading to the defective adipose tissue expression of degs1 in 
human and rodent obesity is unknown. Here, we have shown that TNFα, a mediator of 
obesity induced inflammation and insulin resistance, decreases the transcriptional 
expression of degs1 in cultured adipocytes, which suggests that low chronic 
inflammation may contribute to DEGS1 dysfunction. Other obesity associated 
processes, such as increased oxidative stress and hypoxia, have been shown to impair 
DEGS1 activity and increase DhCer levels(26). Our results also show a positive 
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association between levels of the proadipogenic pparγ2 isoform and degs1 in adipose 
tissue, and given the documented downregulation of pparγ2 in adipose tissue in obese 
insulin resistant states, it is conceivable that decreased levels of pparγ2 may contribute 
to the defective expression of degs1 associated to obesity. 
Studies in rodents have shown that Cer are increased in the WAT of animals fed 
HFD(5) concomitantly with the onset of insulin resistance(6). Results from ob/ob mice 
and human obese studies are more unclear, where both increased or decreased levels of 
ceramides have been reported(7; 8). This suggests that Cer synthesis may be dependent 
on the severity of the obese state and the strength of the adaptive homeostatic responses 
attempting to restore their normal balance. 
Our pharmacological and gene ablation studies have shown that inhibition of DEGS1 
is associated with oxidative stress, cellular death, impaired adipocyte differentiation, 
impaired lipid accumulation and impaired basal lipolysis in mature adipocytes.  
 
Our in vitro studies revealed that the defect in adipogenesis programme caused by 
depletion of DEGS1 occurs during the early stages of adipogenesis (MCE) when 
PPARγ controls the expression of genes that regulate the cell cycle, by directly 
interacting with cyclin D3. Another cyclin involved in adipocyte differentiation is 
cyclin D1, and here we show that downregulation of DEGS1 blocks PPARγ activity and 
cyclins such as D1, D3, E, as well as decreasing cdk2, which modulates PPARγ activity 
during adipogenesis. These data are consistent with studies showing that 
downregulation of degs1 by siRNA inhibits cell growth and arrests the cell cycle in 
cancer cells(12), and where its overexpression increased cell migration and 
metastasis(27). 
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  The pharmacological inhibition of DEGS1 in vivo validated the results obtained 
in vitro and strengthen the concept that functional degs1 is required for the full 
differentiation of preadipocytes into mature adipocytes. 
 We also provide evidence that both pharmacological and genetic ablation of degs1  
certainly increased DhCer levels in in vitro models which according to our results in 
in vitro models may directly block adipocyte differentiation and lipid deposition. This 
effect on lipid accumulation was more severe when the treatment was administered 
during the first three days of differentiation, suggesting a direct impact of DhCer 
accumulation during early stages of adipogenesis.  We also provide evidence showing 
that accumulation of DhCers can also directly repress the transcriptional activity of 
PPARγ and hence could contribute to impair the capacity of the preadipocytes to 
develop a full adipogenic programme.  
These observations strengthen the concept that DhCers are not merely inert precursors 
of ceramides. Nevertheless, the molecular mechanism linking DhCers accumulation and 
dysregulation of the cell cycle and other cellular events remains elusive. One possible 
mechanism is that changes in the DhCer/Cer ratio may disrupt membrane dependent 
structures by altering the levels of cholesterol and/or caveolin in lipid rafts, which are 
known to be highly sensitive to sphingomyelin pool. Alternatively, changes in the 
DhCer/Cer ratio may disturb the global phospholipidome, potentially altering 
membrane-associated processes relevant to adipocyte function. These are important 
questions to address in future research. 
 
In summary, our results indicate that defects in DEGS1 in the context of the MetS may 
compromise adipose tissue expansion and function through the combined inhibition of 
adipogenesis, promotion of cell death and oxidative stress due to the direct 
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accumulation of DhCers. Thus, our data suggests that the selective manipulation of 
DEGS1 and/or its substrates in WAT may be a pathophysiologically advantageous 
strategy to improve adipose tissue homeostasis and ameliorate the burden of obesity 
associated metabolic complications. 
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FIGURE LEGENDS 
FIG.1.(A)Tissue distribution of degs1 (B) Correlation of degs1 mRNA expression and 
fat pad size. The Spearman correlation coefficients were calculated to estimate the 
linear correlations between variables. The rejection level for a null hypothesis was p < 
0.01. Data from 14 lean mice (C-E) Expression levels of degs1 mRNA in response to 
HFD (F-H)Expression levels of degs1 mRNA in ob/ob mice. Mean ± Sem for 6 to 8 
animals per group. *p<0.05 vs. wt. WAT, white adipose tissue; BAT, brown adipose 
tissue; SKM, skeletal muscle: HFD, High fat diet; WT, wild type; IngFat; Inguinal Fat; 
gWAT; gonadal white adipose tissue.  
 
FIG.2(A)mRNA expression of degs1 in 3T3-L1 treated with shRNA against degs1(B 
and C)Cell proliferation (XTT and BrdU assays every 24h until 96h and 72h 
respectively)(D) mRNA expression of Cdk2, Bcl2, Bax and Caspase3. (E) Apoptosis 
and cell death rate (F) Protein expression of Cdk2 (G) Oxygen consumption rate (OCR) 
(H)mRNA expression of antioxidant machinery genes. (I)Reactive oxidative species 
production (ROS)(J)Mitochondria levels. All these experiments were perfomed in 
degs1KD and wild type 3T3-L1 cells. Mean±Sem of three separate experiments 
performed in triplicate; *p< 0.05.  
FIG.3.(A)mRNA expression of degs1 in 3T3-L1 cells during adipocyte 
differentiation.(B)Lipid accumulation at d9 of differentiation, Oil Red O Staining (C) 
mRNA expression of PREF1 in wild type and degs1 KD cells during differentiation. 
(D)mRNA expression of genes involved in adipocyte differentiation and lipid 
accumulation. Mean±Sem of three separate experiments performed in triplicate; *p< 
0.05. 
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FIG.4. 3T3-L1 cells treated with C8-CPPC and/or Rosiglitazone (A and B) mRNA 
expression of genes involved in adipocyte differentiation and lipid accumulation at 
24 and 48h after induction. (C) Protein expression levels of PPARγ2 and cEBPα 
(D) Lipid content after 48 and 96h of differentiation.  Mean ± Sem of two separate 
experiments performed in triplicate. One way ANOVA was used to analyze 
statistical significance between treatments at 24 h and 48 h. Significant differences 
(Duncan; p<0.05) are indicated with different words. (E) Dihydroceramide and 
ceramide levels after 48h of differentiation. Mean ± Sem of two separate 
experiments performed in triplicate p<0.05. 
FIG.5. C8-CCP inhibitor increases proliferation and decreases lipid accumulation in 
preadipocytes in vivo. 10 weeks old mice were given a 45% HF diet for 5 weeks before 
treated intraperitoneally with vehicle or C8-CCP inhibitor (2mg/kg/day) during 9 days. 
(A) Representative images of immunofluorescence analysis of gonadal adipose tissue 
of control (vehicle) and C8-CCP-treated mice are presented with Pref-1 (Cyan) and ki-
67 (red, white arrows). Nuclei and lipids are respectively stained with Hoechst (blue) 
and Bodipy (green). Scale bar 100 or 20 µm. Quantification of preadipocytes (left 
graph, % Pref-1 positive cells/total cells) and Ki67 (white bars) /Bodipy (dark grey 
bars) positive cells among preadipocytes (Pref-1 positive cells, grey bars). (B) mRNA 
expression of  preadipocyte markers and pparg, desg1, adiponectin, caspase 3 and fas in 
gonadal adipose tissue of control and C8-CCP-treated mice. n=7-8 mice per 
experimental group; mean±SEM;*p<0.05, ***p<0.0001 versus vehicle 
 
FIG.6. (A) Glycerol release in 3T3-L1 adipocytes exposed 48h with C8-CPPC and 
stimulated with nor-adrenalin (NA) for 6h. (B-D) Results from Western blot analysis for 
p-HSL/HSL ratio and total HSL in 3T3L1 adipocytes exposed 48h with C8-CPPC and 
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stimulated with NA for 6h. Graphs show the mean ± SEM of two separated 
experiments; p< 0.05, 
&
p<0.05 vs cells without NA and 
#
p<0.05 vs cells without NA or 
treated with 10
-8
M NA. (E) Effects of pharmacological inhibition of DEGS1 on insulin 
signalling. Results from Western blot analysis for p-AKT and AKT in 3T3-L1 
adipocytes exposed 48h or 72h with C8-CPPC 1µM and increased concentrations of 
Insulin (10 nM-100 nM) for 15min. (F and G9) Results from Western blot analysis for 
Glut4 and adiponectin in 3T3-L1 adipocytes exposed with C8-CPPC 0.5-1µM and 
Insulin (100 nM) for 48 hours.  (H) Results from Western blot analysis for AMPK in 
3T3-L1 adipocytes exposed with C8-CPPC 0.5-1µM and insulin (100nM), rosiglitazone 
(1 nM) and metformin (100 nM ) for 48 hours.
 b
p< 0.05 versus untreated cells (Insulin, 
Rosi or Metformin effect) and; 
b
p< 0.05 versus 0 µM C8-CPPC (C8-CPPC effect) 
 
FIG.7. (A and B) Dihydroceramides impair adipocyte differentiation during early 
adipogenesis. 3T3L1 preadipocytes treated withC2-DhC (50µM) for a period of 48h at 
d0 or at d3 of differentiation. ORO staining and mRNA expression of adipogenesis and 
lipid metabolism genes. Mean ± Sem of two separated experiments performed in 
triplicate; *p< 0.05 vs. control. (C) Dihydroceramides decrease ligand-mediated PPARγ 
transactivation. Cells were treated with DMSO as a control group, Rosiglitazone 10uM,  
GW1929 10uM, C2 and C16 dihydroceramides and ceramides 100 uM as indicated. 
Graphs represent the average of 3 independent experiments.  p< 0.05.  (*) vs control 
cells, (#) vs Rosiglitazone and (&) vs GW1929. 
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ABSTRACT 
Adipose tissue dysfunction is an important determinant of obesity-associated lipid 
induced metabolic complications. Ceramides are well known mediators of lipid induced 
insulin resistance in peripheral organs such as muscle. DEGS1 is the desaturase 
catalysing the last step in the main ceramide biosynthetic pathway. Functional 
suppression of DEGS1 activity results in substantial changes in ceramide species likely 
to affect fundamental biological functions such as oxidative stress, cell survival and 
proliferation. Here, we show that degs1 expression is specifically decreased in the 
adipose tissue of obese patients and murine models of genetic and nutritional obesity. 
Moreover, loss of function experiments using pharmacological or genetic ablation of 
DEGS1 in preadipocytes prevented adipogenesis and decreased lipid accumulation. 
This was associated with elevated oxidative stress, cellular death and blockage of the 
cell cycle. These effects were coupled with increased dihydroceramide content.  Finally, 
we validate in vivo that pharmacological inhibition of DEGS1 impairs adipocyte 
differentiation. These data identify DEGS1 as a new potential target to restore adipose 
tissue function and prevent obesity-associated metabolic disturbances. 
 
 
KEYWORDS: Adipocyte function, adipose tissue, DEGS1, obesity, insulin resistance 
and dihydroceramides 
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Dysfunction of white adipose tissue (WAT) and impaired differentiation of new 
adipocytes may lead to lipid leakage and inappropriate accumulation of ectopic lipids in 
peripheral organs, causing lipotoxicity and the Metabolic Syndrome(1). The toxic 
effects of lipids are determined by both the quantity and also by their qualitative 
characteristics(2). Whereas it is well documented that specific species of sphingolipids 
and ceramides mediate lipotoxicity in liver and muscle(3; 4), the contribution of specific 
lipotoxic species to WAT dysfunction in the context of obesity is still not well defined. 
It is known that in rodent WAT, ceramides increase in response to HFD(5; 6) 
concomitantly with the onset of insulin resistance(6). Lipid analysis of WAT from 
human obese subjects has produced conflicting results, showing either increased or 
decreased ceramide levels in obese and insulin resistant patients(7; 8). 
Ceramides can be synthesised from sphingomyelins, but the main contributor to their 
biosynthesis is the de novo pathway. The final reaction of the de novo pathway is 
catalyzed by a ∆4-dihydroceramide desaturase (DEGS1) that adds a 4,5-trans-double 
bound on the sphingoid base of the dihydroceramide (DhCer) (9). The other enzyme, 
DEGS2 catalyzes the synthesis of phytoceramides(10), whose expression is restricted to 
skin, intestine and kidney. 
There is evidence that downregulation of degs1 increases the DhCer/Cer ratio in 
different cellular models. Although DhCer was considered an inactive precursor of 
ceramides(11), recent studies have suggested their relevance as modulators of cell cycle, 
apoptosis, autophagy or oxidative stress(12; 13), processes that a priori are expected to 
compromise the development and function of adipose tissue. 
Since DEGS1 is the key enzyme regulating the DhCer/Cer ratio, understanding its 
regulation is important in determining the pathophysiological relevance of this pathway 
in adipose tissue. Of note, degs1 has recently been identified in a GWAS study as a 
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candidate gene associated with fat mass accumulation in mice(14) further suggesting 
that DEGS1 may be relevant for the adaptive accretion of adipose tissue. Moreover, 
DEGS1 could be considered an attractive therapeutic target for obesity-associated 
insulin resistance, since Fenretinide has been claimed to improve insulin sensitivity by 
inhibiting DEGS1(15), although other molecular targets cannot be ruled out.  
Here we show that DEGS1 expression is selectively perturbed in the WAT of murine 
models of nutritional and genetically induced obesity and in WAT of morbidly obese 
patients. In vitro analysis revealed that both pharmacological inhibition and genetic 
ablation of DEGS1 results in impaired adipocyte differentiation and lipid accumulation, 
effects mediated by increased dihydroceramide content. In vivo, pharmacological 
inhibition of DEGS1 also resulted in impaired adipocyte differentiation. Decreased 
levels of DEGS1 were associated with increased oxidative stress, accelerated cellular 
death and blockage of cell cycle. We also show data supporting that DEGS1 expression 
is regulated by PPARγ.  
RESEARCH DESIGN AND METHODS 
Mice husbandry 
Animals were housed at 22-24°C with 12h light/dark cycles. Food and water were 
available ad libitum. Lean wildtype, PPARγ2
−/−
 and PPARγ2
−/−
xob/ob mice (POKO) 
(16) were used for profiling purposes. Mice were placed on a normal chow diet 
(D12450B) or in HFD (D12451) from Research Diets. 
For the pharmacological inhibition of DEGS1, 10 weeks-old male C57BL/6 WT mice 
were used.  Mice were given a HFD for 5weeks before C8-CPPC (Matreya) 
administration. All protocols used were approved by the UK Home Office. 
Intraperitoneal injection of cyclopropenylceramide.  
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Mice were distributed in 2 groups (n=8) and administered daily vehicle (2-
hydroxypropyl betacyclodextrine) or C8-CPPC (2mg/kg/day) for 9d via intraperitoneal 
injection. Mice were culled at the end of the experiment and WAT| was removed for 
gene expression and microscopy analysis. No differences in food intake, lean mass and 
fat content were observed during the treatment. 
Ex vivo experiments in isolated mature adipocytes 
Adipocytes from gonadal WAT of 16weeks C57BL/6 mice were obtained by 
collagenase type II digestion at 37ºC. After digestion, adipocytes were placed in DMEM 
media with or without 1µM C8-CPPC every 5h for a total period of 20h. 
Retroviral Short Hairpin RNA Constructs for DEGS1 
A RNAi-Ready pSIREN-RetroQ vectors (BD Biosciences) were used to target degs1 in 
3T3L1-cells. Sequences targeting degs1 were ligated into the pSIREN vector as 
described in manufacturer’s instructions. Retroviruses were generated by transfecting 
BOSC cells (ATCC) with the pSIREN plasmids using FuGene6 (Roche). Supernatant 
with the viral content was used to transfect 3T3-L1 preadipocytes. 24h after retroviral 
infection, the cells were selected with puromycin (4µg/ml).  
Culture, differentiation and treatment of 3T3-L1 preadipocytes 
Cells were differentiated into adipocytes (day9) accordingly to the protocol described in 
(17) with or without rosiglitazone 0.1µM. Lipid accumulation was assessed by Oil red 
O solution(18). 
Pharmacological inhibition of DEGS1 activity in vitro. 
Effects on differentiation. At day 0 of differentiation, 3T3-L1 cells were treated with 
C8-CPPC 1µM and/or Rosiglitazone 0.1µM for 96h.  
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Effects on lipolysis.On day 8 of differentiation, after 48h treatment with C8-CPPC 1µM 
the cells were exposed to Noradrenaline (NA) (10
−8
 M and 10
−7
 M) for 6h. 
Effects on insulin signalling. On day 8 of differentiation, after 48h treatment with C8-
CPPC 1µM the cells were exposed to insulin (10nM and 100nM) for 15min.  
Effects on glut4, adiponectin. On day 8 of differentiation, after 48h treatment with C8-
CPPC 0.5-1µM the cells were exposed to insulin.  
Effects on AMPK. On day 8 of differentiation, after 48h treatment with C8-CPPC 0.5-
1µM the cells were exposed to insulin (10nM and 100nM), rosiglitazone (1nM and 
10nM) and metformin (100nM) for 24h.  
Dihydroceramide treatment.  
3T3-L1 preadipocytes were treated at day 0 of differentiation with the induction cocktail 
and C2DhCer at 50µM for 3d, and a second batch of cells were exposed at day 3 of 
differentiation and treated with C2DhCer at 50µM for 3d. All batches were taken until 
final differentiation at day 9. 
Human samples 
The cohort included 28 morbidly obese (MO) and 6 non-obese subjects with no 
alterations to lipid or glucose metabolism, as controls (Table I). Approval for the study 
was given by the ethics committee and all patients gave their informed consent. Visceral 
adipose tissue biopsies were obtained from MO patients undergoing bariatric surgery 
(Scopinaro procedure) or laparoscopic surgery (hiatus hernia repair or 
cholecystectomies) for the lean subjects. 
 
 
Western blotting 
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Protein extracts were prepared using the Nuclear and Cytoplasmic Extraction Reagents 
Kit (Pierce) according to manufacturer’s instructions. Immunoblots were incubated with 
the following antibodies: PPARγ, C/EBPβ, CyclinA, (Santa Cruz) CyclinB1, D1, D3 
and E1,cdk4, AKT, Ser473-pAKT, p44/42 MAPK, phospho-p44/42 MAPK, Ser660-
pHSL, Ser565-pHSL, total HSL, ATGL, caveolin-1, plin1, glut4, adiponectin, and 
AMPK (Cell Signalling), adfp/adrp and abhd5 and anti-β-Actin (Abcam).  
RT-PCR 
RNA was extracted using TRI Reagent (Sigma) and reverse-transcribed to cDNA. Real-
Time PCR using SYBRgreen was performed according to manufacturer’s instructions 
(ABI). Primer sequences were obtained from Primer Blast(19). Expression of genes was 
corrected by the geometrical average of 18s, β2m, β-act, and 36b4 using Bestkeeper 
(20).  
Apoptosis: combined Annexin-V/propidium iodide staining 
Viability was assessed by using an Annexin-V/propidium iodide kit (Bender 
MedSystems), according to manufacturer's recommendations. Binding of fluorescein-
conjugated Annexin-V and propidium iodide was measured by FACSCalibur(BD). 
Cellular proliferation:  
Cell viability was assessed using an XTT colorimetric assay (Roche) following the 
protocol supplied by the manufacturer. Cell proliferation was analyzed by quantification 
of the incorporation of bromodeoxyuridine (Roche). 
Bodipy staining, Reactive Oxygen Stress (ROS) production and mitochondrial 
content. 
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Cells were incubated with Bodipy at 4ºC or alternatively with 20µM DCF-DA or 
100nM Mitotracker (Invitrogen) at 37°C for 30 min and analysed on a FACSCalibur. 
Cellular oxygen consumption 
Cells were exposed to oligomycin (1µM), C8-CPPC (0.9µM) and Antimycin/Rotenone 
(1µM each); O2 consumption was measured using the XF24 analyzer (Seahorse 
Bioscience) for a period of 90min. 
 
Whole-mount confocal microscopy 
Gonadal adipose tissue was fixed in 4% paraformaldehyde. Samples were incubated at 
4°C with mouse pref-1 or rabbit Ki67 primary antibodies. Nuclei and neutral lipids were 
stained with Hoechst 33342, and BODIPY 493/503 respectively. Sample examination 
was performed using a Zeiss 510 confocal laser scanning microscope (Carl Zeiss). 
Pref1, Ki67, Bodipy positive cells and total cells (up to 913 cells/field) were 
automatically counted by using Image J software in 3 independent fields in each tissue. 
Light microscopy analysis  
Samples for adipose tissue H&E staining were prepared as described elsewhere (16). 
Adipocyte sizes were measured using Cell P (Olympus soft Imaging Solutions GMBH).  
Between 1000-3000 adipocytes from each mouse were used to obtain the mean cell-
area. 
 
 
Luciferase reporter assay 
HEK293 cells were transfected using Lipofectamine LTX (Invitrogen), following the 
manufacturer's instructions. 75ng of the reporter plasmid (3xPPRE TKLuc) and 37.5ng 
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of the eukaryotic expression vector (pSV-PPARγ) were cotransfected to each well. The 
plasmid pRL-CMV (5ng/well) was included as an internal control. 24h post transfection 
cells were treated as indicated (DMSO, Rosiglitazone 10µM, GW1929 10µM, C2 and 
C16 DhCers and Cer 100 µM). Luciferase assays were performed using the dual 
luciferase reporter assay system (Promega).  
Lipidomics 
Cells were mixed with 0.9% NaCl and sonicated for 5 min at 5 ºC, 40 kHz. Samples 
were spiked with internal standard (IS). The samples were extracted with 
chloroform:methanol (2:1). The lower phase was collected and mixed with the labeled 
standard mixture (three stable isotope-labeled reference compounds). Lipid extracts 
were analyzed on a Q-ToF Premier mass spectrometer (Waters) combined with an 
Acquity Ultra Performance Liquid chromatography(UPLC/MS). The data was 
processed using MZmine software. The lipids were quantified by normalizing with 
corresponding IS.  
Statistical analysis 
Student t-test (unpaired), ANOVA and Duncan test were used for the statistical 
analysis. Statistically significance was set at p<0.05 and p<0.01. Spearman correlation 
was calculated to estimate the linear correlations between variables p<0.01. 
 
 
RESULTS 
DEGS 1 is downregulated in WAT in obese murine models. 
Tissue distribution analysis showed that degs1 is present in most tissues and it is 
particularly highly expressed in adipose tissue, liver and muscle, whereas degs2 mRNA 
is only detected in intestine (Fig. 1A). Degs1 expression in vivo was positively 
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correlated with WAT mass in lean healthy mice (Fig. 1B). However, this correlation 
was disrupted in murine models of nutritional and genetically induced obesity (HFD 
and ob/ob), where degs1 mRNA expression was decreased vs. controls (Fig.1C and 1F). 
Of note, the dysregulation of degs1 in obesity was limited to WAT, as its expression in 
liver or skeletal muscle was not affected in either HFD fed mice (Fig.1D and 1E) or in 
ob/ob mice (Fig.1G and H). DEGS1 was preferentially expressed in matured adipocytes 
vs. stromal vascular fraction (svf) in lean and ob/ob mice (Fig.S1) and downregulated in 
ob/ob adipocytes vs lean adipocytes. Moreover, this downregulation of degs1 in total 
WAT of HFD fed and ob/ob mice was also recapitulated in visceral AT of morbidly 
obese patients (Fig S2A). 
To determine whether the decrease in degs1 expression was part of a global adaptation 
of de novo ceramide synthesis pathway in obesity, the expression of other genes in this 
pathway were measured. Expression of the sptlc1 and sptlc2 subunits were not changed 
in human visceral AT, nor in ob/ob WAT, but sptlc2 expression was increased in HFD 
WAT (Fig S2B-C). Moreover, both HFD and ob/ob mouse WAT exhibited a reduction 
in a subset of ceramide synthases, suggests a possible defect in the synthesis of specific  
subset of ceramides.  
We then confirmed that modulators of obesity associated inflammation may contribute 
to the downregulation of degs1, as treatment of 3T3-L1 adipocytes with TNFα (5 ng/ml 
and 10ng/ml) for 48h resulted in a dose dependent downregulation of degs1 mRNA 
expression (38.8±3.6% and 45.7±7.3%  reduction respectively).  
We then investigated a link between DEGS1 and the adipogenic programme. It is 
known that obese and insulin resistant murine models and humans have reduced 
expression of pparγ2 in WAT. Furthermore we observed that expression of pparγ2 and 
degs1 were directly correlated in 3T3-L1 after treatment with Rosiglitazone (Fig.S3A). 
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To validate this in vivo, we analyzed the regulation of degs1 in adipose tissue, liver and 
skeletal muscle of pparγ2KO and the POKO mice(16). WAT of pparγ2KO and POKO 
mice expressed significantly lower degs1mRNA levels vs. wt (Fig.S3B). This 
association was restricted to WAT since the expression of degs1 in other metabolic 
organs such as skeletal muscle or liver was not affected when pparγ2 was absent 
(Fig.S3C and D). 
 
DEGS1 controls important cellular functions such as proliferation, survival and 
oxidative stress in 3T3-L1 adipocytes. 
A stable degs1 knock-down 3T3-L1 cell line (65%) (Fig.2A) resulted in inhibition of 
cell growth after 24h (Fig.2B-C). Degs1 knock-down also induced cell death (13.7%) 
and apoptosis (6.3%)(Fig.2E). These were associated with a decrease in cyclin-A and 
cdk2 in degs1KD proliferating cells (Fig.2F) as well as elevated Bax and caspase-
3mRNA (Fig.2D). Elevated reactive oxygen species (ROS) production (Fig.2I) along 
with an upregulation of the expression of antioxidant genes was observed in degs1KD 
preadipocytes (Fig.2H). This was accompanied by impaired mitochondrial oxygen 
consumption (Fig.2G) without changes in the number of mitochondria (Fig.2J).  
 
DEGS1 is required for adipocyte differentiation. 
Expression of degs1 is increased during normal differentiation of 3T3-L1 adipocytes 
(Fig.3A). To investigate whether ablation of DEGS1 affected adipogenesis, 3T3-L1 
degs1KD cells were induced to differentiate. At d9, degs1KD cells showed impaired 
lipid accumulation vs. controls (Fig.3B). Moreover, pref1 mRNA expression, a marker 
for preadipocytes was not decreased in degs1KD cells at d9 suggesting that a relevant 
number of cells remained in the preadipocyte stage (Fig.3C). In addition, expression of 
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proadipogenic and lipogenic genes were downregulated (Fig.3D). Interestingly, 
treatment with rosiglitazone only partially improved the differentiation and lipid 
accumulation rates of degs1KD cells (Fig. S4A-B).  
We tested whether DEGS1 expression may affect the mitotic clonal expansion (MCE).  
In degs1KD cells, pparγ and cebpβ were downregulated compared to controls at time 0 
and 24h following differentiation induction (Fig. S5AB). The expression of PPARγ and 
several cyclins involved in adipogenesis were measured at earlier time points. We noted 
a strong effect of degs1 depletion on PPARγ2 mRNA from time 0. Additionally,   
reduced levels of degs1 blocked MCE as indicated by the inhibition of cyclin D1 and 
cdk2 expression between time 0 and 4h hours after the induction (Fig. S5AB). Cyclin E 
and cyclin D3 expression was also inhibited but at later time points. 
 
 
 
Pharmacological inhibition of DEGS1 recapitulates DEGS1KD antiadipogenic 
phenotype. 
Use of C8-cyclopropenylceramide (C8-CPPC), a selective inhibitor of DEGS1(21) 
further confirmed the relevance of DEGS1 in adipogenesis. Similarly to degs1KD cells, 
3T3-L1 cells were induced to differentiate and treated simultaneously with C8-CPPC 
from time 0h every 6h for 48h. C8-CPPC decreased the expression of proadipogenic 
transcription factors such as PPARγ and C/EBPβ as well as lipogenic genes (Fig. 4AC). 
The antiadipogenic effect of C8-CPPC persisted after Rosiglitazone treatment (Fig. 
4AC). As expected, analysis of neutral lipids showed that 3T3-L1 cells treated with C8-
CPPC for 96h accumulated significantly less lipids compared to untreated cells (Fig. 
4D).  
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Pharmacological inhibition of DEGS1 also impairs adipocyte differentiation in 
vivo. We administered C8-CPPC IP to mice fed a HFD for 5weeks, an experimental 
protocol known to trigger adipocyte hyperplasia. Molecular analysis of the WAT from 
mice treated with C8-CPPC presented higher levels of pref-1+ cells, suggesting an 
increase in the number of preadipocytes vs. controls. Interestingly, a significant number 
of preadipocytes showed evidence of increased proliferation (Ki67+) whereas the 
number of differentiating preadipocytes (pref1+, bodipy +) was significantly smaller in 
comparison to controls (Fig.5A).  These data were reinforced at mRNA level by 
showing increased expression of pref-1 and gata2 (Fig 5B) and the presence of less 
smaller adipocytes in treated mice (Fig.S6). Altogether, these data suggest C8-CPPC 
mediated inhibition of DEGS1 impaired the capacity of preadipocytes to differentiate 
into adipocytes in vivo. 
 
DEGS1 is required for lipid accumulation, basal lipolysis and glucose uptake in 
mature adipocytes. 
We next focused on the effects of DEGS1 inhibition in fully differentiated adipocytes 
by treating isolated mature adipocytes-from the gonadal adipose tissue of C57BL/6 
mice- with C8-CPPC for 24h. C8-CPPC caused a decrease in the expression of lipid 
metabolism genes as well as an increase in antioxidant genes (Fig S7) recapitulating our 
observations in 3T3L1 preadipocytes. 
 
We further investigated the effects of inhibiting DEGS1 on lipolytic activity and insulin 
signalling, and measured adiponectin expression as a representative fingerprint of global 
adipocyte homeostasis in mature differentiated 3T3L1 adipocytes. Thus, we observed 
that basal lipolytic activity was decreased in mature differentiated 3T3L1 adipocytes 
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when treated with C8-CPPC in non-stimulated conditions (Fig. 6A). Systematic 
evaluation of the lipolytic axis showed that under basal conditions, phosphorylation of 
Ser565 was also substantially increased by C8-CPPC concomitantly with a minor 
downregulation of Ser660 phosphorylation (Fig.6B-D) suggesting a decreased HSL 
activity. Moreover, total levels of HSL were also decreased in C8-CPPC treated cells. 
These data suggest that pharmacological inhibition of DEGS1 in mature adipocytes 
disrupts the lipolytic response under non-stimulated conditions a defect that was 
superseded in the presence of NA.  
 
Finally we characterised the effects of pharmacological inhibition of DEGS1 on insulin 
signalling in 3T3-L1 mature adipocytes treated with C8-CPPC for 48h as described 
above, and subsequently incubated in the presence of increasing doses of insulin. No 
major differences where observed in the phosphorylation of AKT in C8-CPPC treated 
cells after acute insulin stimulation (Fig.6E). However, we found that Glut4 protein 
levels were increased in C8-CPPC treated cells, suggesting that glucose uptake may be 
increased (Fig.6F). Interestingly, we also did not observe any differences in either 
adiponectin levels in response to C8-CPPC or in AMPK phosphorylation, a known 
inducer of adiponectin, although increased levels of tAMPK were observed (Fig 6GH). 
 
Both, Pharmacological and Genetic inhibition of DEGS1 increases 
dihydroceramide/ceramide ratio in 3T3-L1-cells. 
 
We confirmed that C8-CPPC increased the DhCer/Cer ratio in 3T3L-1 preadipocytes 
upon inhibition of DEGS1 (Fig.4E). Similarly, degs1KD preadipocytes (d0) exhibited 
an increased DhCer/Cer ratio vs. controls. Downregulation of degs1 expression in 
degs1KD cells was accompanied by a dowregulation of serine palmitoyltransferase 
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(sptlc1) and Ceramide synthase 6 (Cers6), suggestive of a homeostatic readjustment of 
the biosynthetic pathway to compensate for the dysfunction of degs1. Other genes 
related to ceramide homeostasis such as neutral ceramidase (ncdase), and 
glycosylceramide synthase (gcs) were  also downregulated. 
Curiously, at d9, degs1KD cells, despite impaired differentiation, showed a complete 
restoration of the DhCer/Cer ratio (indicated by the normalization of the ceramide pool) 
(Fig.S8A). This could be partially explained by a compensation mechanism, mediated 
by downregulation of neutral ceramidases and the conversion of sphyngomyelins to 
ceramides (upregulation of sphyngomyelinase 2) (Fig.S8B).  
 
The Impairment of adipocyte differentiation during early adipogenesis by DEGS1 
inhibition is recapitulated by Dihydroceramides per se.  
We finally sought to validate whether DhCer by itself could mediate the effects of 
DEGS1 inhibition on adipocyte differentiation in our models of genetic or 
pharmacological inhibition of degs1. 3T3-L1cells were treated with C2-DhCer during a) 
the MCE at time 0 and b) at day 3 after differentiation. DhCer inhibited lipid 
accumulation (Fig.7A) and the expression of genes involved during the early stages of 
adipogenesis (Fig. 7B).  
Since synthetic sphingolipid analogues are known to modulate PPARs activity(22), we 
investigated whether both C2 and C16 DhCer could exert a repressive effect on PPARγ 
activation in the presence of the PPARγ ligands (Fig. 7C). Our results show that DhCer 
can also block the ligand-mediated transactivation of PPARγ. Similar results were 
obtained with ceramides, indicating these effects were not a consequence of the 
unsaturation of the sphingoid moiety (data not shown). 
DISCUSSION 
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The DhCer/Cer ratio has an important homeostatic regulatory role in the cell, 
contributing to cell survival, autophagy and oxidative stress(12; 13). Here we identify 
DEGS1 as an essential metabolic enzyme which is dysregulated in obese states and 
contributes to adipose tissue dysfunction. Our complementary in vitro and in vivo 
approaches reveal that reduced DEGS1 function impairs adipogenesis and lipogenesis 
programmes and increases oxidative stress.  
DEGS1 is expressed in WAT and correlates in rodents with fat mass in healthy states, 
an association that is disrupted in severe forms of obesity. Expression of DEGS1 in liver 
or muscle is not affected by obesity, further indicating that the WAT is particularly 
susceptible to changes in ceramide metabolism in obese states. The relevance to human 
obesity is confirmed by the downregulation of DEGS1 in the adipose tissue of morbidly 
obese patients, and by recent reports showing that DhCer rather than Cer content 
positively correlates with BMI and waist circumference in cohorts of overweight-obese 
subjects(23; 24). To date, only a single functional mutation in the Degs1gene has been 
reported in humans  where patients demonstrate increased serum DhCer and decreased 
cholesterol esters, and decreased waist to hip ratio(25). Globally considered, these data 
suggest the existence of an association between DEGS1 function and fat mass. 
The molecular mechanism leading to the defective adipose tissue expression of degs1 in 
human and rodent obesity is unknown. Here, we have shown that TNFα, a mediator of 
obesity induced inflammation and insulin resistance, decreases the transcriptional 
expression of degs1 in cultured adipocytes, which suggests that low chronic 
inflammation may contribute to DEGS1 dysfunction. Other obesity associated 
processes, such as increased oxidative stress and hypoxia, have been shown to impair 
DEGS1 activity and increase DhCer levels(26). Our results also show a positive 
association between levels of the proadipogenic pparγ2 isoform and degs1 in adipose 
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tissue, and given the documented downregulation of pparγ2 in adipose tissue in obese 
insulin resistant states, it is conceivable that decreased levels of pparγ2 may contribute 
to the defective expression of degs1 associated to obesity. 
Studies in rodents have shown that Cer are increased in the WAT of animals fed 
HFD(5) concomitantly with the onset of insulin resistance(6). Results from ob/ob mice 
and human obese studies are more unclear, where both increased or decreased levels of 
ceramides have been reported(7; 8). This suggests that Cer synthesis may be dependent 
on the severity of the obese state and the strength of the adaptive homeostatic responses 
attempting to restore their normal balance. 
Our pharmacological and gene ablation studies have shown that inhibition of DEGS1 is 
associated with oxidative stress, cellular death, impaired adipocyte differentiation, 
impaired lipid accumulation and impaired basal lipolysis in mature adipocytes.  
 
Our in vitro studies revealed that the defect in adipogenesis programme caused by 
depletion of DEGS1 occurs during the early stages of adipogenesis (MCE) when PPARγ 
controls the expression of genes that regulate the cell cycle, by directly interacting with 
cyclin D3. Another cyclin involved in adipocyte differentiation is cyclin D1, and here 
we show that downregulation of DEGS1 blocks PPARγ activity and cyclins such as D1, 
D3, E, as well as decreasing cdk2, which modulates PPARγ activity during 
adipogenesis. These data are consistent with studies showing that downregulation of 
degs1 by siRNA inhibits cell growth and arrests the cell cycle in cancer cells(12), and 
where its overexpression increased cell migration and metastasis(27). 
  The pharmacological inhibition of DEGS1 in vivo validated the results obtained in 
vitro and strengthen the concept that functional degs1 is required for the full 
differentiation of preadipocytes into mature adipocytes. 
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 We also provide evidence that both pharmacological and genetic ablation of degs1  
certainly increased DhCer levels in in vitro models which according to our results in in 
vitro models may directly block adipocyte differentiation and lipid deposition. This 
effect on lipid accumulation was more severe when the treatment was administered 
during the first three days of differentiation, suggesting a direct impact of DhCer 
accumulation during early stages of adipogenesis.  We also provide evidence showing 
that accumulation of DhCers can also directly repress the transcriptional activity of 
PPARγ and hence could contribute to impair the capacity of the preadipocytes to 
develop a full adipogenic programme.  
These observations strengthen the concept that DhCers are not merely inert precursors 
of ceramides. Nevertheless, the molecular mechanism linking DhCers accumulation and 
dysregulation of the cell cycle and other cellular events remains elusive. One possible 
mechanism is that changes in the DhCer/Cer ratio may disrupt membrane dependent 
structures by altering the levels of cholesterol and/or caveolin in lipid rafts, which are 
known to be highly sensitive to sphingomyelin pool. Alternatively, changes in the 
DhCer/Cer ratio may disturb the global phospholipidome, potentially altering 
membrane-associated processes relevant to adipocyte function. These are important 
questions to address in future research. 
 
In summary, our results indicate that defects in DEGS1 in the context of the MetS may 
compromise adipose tissue expansion and function through the combined inhibition of 
adipogenesis, promotion of cell death and oxidative stress due to the direct 
accumulation of DhCers. Thus, our data suggests that the selective manipulation of 
DEGS1 and/or its substrates in WAT may be a pathophysiologically advantageous 
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strategy to improve adipose tissue homeostasis and ameliorate the burden of obesity 
associated metabolic complications. 
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FIGURE LEGENDS 
FIG.1.(A)Tissue distribution of degs1 (B) Correlation of degs1 mRNA expression and 
fat pad size. The Spearman correlation coefficients were calculated to estimate the 
linear correlations between variables. The rejection level for a null hypothesis was p < 
0.01. Data from 14 lean mice (C-E) Expression levels of degs1 mRNA in response to 
HFD (F-H)Expression levels of degs1 mRNA in ob/ob mice. Mean ± Sem for 6 to 8 
animals per group. *p<0.05 vs. wt. WAT, white adipose tissue; BAT, brown adipose 
tissue; SKM, skeletal muscle: HFD, High fat diet; WT, wild type; IngFat; Inguinal Fat; 
gWAT; gonadal white adipose tissue.  
 
FIG.2(A)mRNA expression of degs1 in 3T3-L1 treated with shRNA against degs1(B 
and C)Cell proliferation (XTT and BrdU assays every 24h until 96h and 72h 
respectively)(D) mRNA expression of Cdk2, Bcl2, Bax and Caspase3. (E) Apoptosis 
and cell death rate (F) Protein expression of Cdk2 (G) Oxygen consumption rate (OCR) 
(H)mRNA expression of antioxidant machinery genes. (I)Reactive oxidative species 
production (ROS)(J)Mitochondria levels. All these experiments were perfomed in 
degs1KD and wild type 3T3-L1 cells. Mean±Sem of three separate experiments 
performed in triplicate; *p< 0.05.  
FIG.3.(A)mRNA expression of degs1 in 3T3-L1 cells during adipocyte 
differentiation.(B)Lipid accumulation at d9 of differentiation, Oil Red O Staining (C) 
mRNA expression of PREF1 in wild type and degs1 KD cells during differentiation. 
(D)mRNA expression of genes involved in adipocyte differentiation and lipid 
accumulation. Mean±Sem of three separate experiments performed in triplicate; *p< 
0.05. 
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FIG.4. 3T3-L1 cells treated with C8-CPPC and/or Rosiglitazone (A and B) mRNA 
expression of genes involved in adipocyte differentiation and lipid accumulation at 24 
and 48h after induction. (C) Protein expression levels of PPARγ2 and cEBPα (D) Lipid 
content after 48 and 96h of differentiation.  Mean ± Sem of two separate experiments 
performed in triplicate. One way ANOVA was used to analyze statistical significance 
between treatments at 24 h and 48 h. Significant differences (Duncan; p<0.05) are 
indicated with different words. (E) Dihydroceramide and ceramide levels after 48h of 
differentiation. Mean ± Sem of two separate experiments performed in triplicate p<0.05. 
FIG.5. C8-CCP inhibitor increases proliferation and decreases lipid accumulation in 
preadipocytes in vivo. 10 weeks old mice were given a 45% HF diet for 5 weeks before 
treated intraperitoneally with vehicle or C8-CCP inhibitor (2mg/kg/day) during 9 days. 
(A) Representative images of immunofluorescence analysis of gonadal adipose tissue 
of control (vehicle) and C8-CCP-treated mice are presented with Pref-1 (Cyan) and ki-
67 (red, white arrows). Nuclei and lipids are respectively stained with Hoechst (blue) 
and Bodipy (green). Scale bar 100 or 20 µm. Quantification of preadipocytes (left 
graph, % Pref-1 positive cells/total cells) and Ki67 (white bars) /Bodipy (dark grey 
bars) positive cells among preadipocytes (Pref-1 positive cells, grey bars). (B) mRNA 
expression of  preadipocyte markers and pparg, desg1, adiponectin, caspase 3 and fas in 
gonadal adipose tissue of control and C8-CCP-treated mice. n=7-8 mice per 
experimental group; mean±SEM;*p<0.05, ***p<0.0001 versus vehicle 
 
FIG.6. (A) Glycerol release in 3T3-L1 adipocytes exposed 48h with C8-CPPC and 
stimulated with nor-adrenalin (NA) for 6h. (B-D) Results from Western blot analysis for 
p-HSL/HSL ratio and total HSL in 3T3L1 adipocytes exposed 48h with C8-CPPC and 
stimulated with NA for 6h. Graphs show the mean ± SEM of two separated 
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experiments; p< 0.05, 
&
p<0.05 vs cells without NA and 
#
p<0.05 vs cells without NA or 
treated with 10
-8
M NA. (E) Effects of pharmacological inhibition of DEGS1 on insulin 
signalling. Results from Western blot analysis for p-AKT and AKT in 3T3-L1 
adipocytes exposed 48h or 72h with C8-CPPC 1µM and increased concentrations of 
Insulin (10 nM-100 nM) for 15min. (F and G9) Results from Western blot analysis for 
Glut4 and adiponectin in 3T3-L1 adipocytes exposed with C8-CPPC 0.5-1µM and 
Insulin (100 nM) for 48 hours.  (H) Results from Western blot analysis for AMPK in 
3T3-L1 adipocytes exposed with C8-CPPC 0.5-1µM and insulin (100nM), rosiglitazone 
(1 nM) and metformin (100 nM ) for 48 hours.
 b
p< 0.05 versus untreated cells (Insulin, 
Rosi or Metformin effect) and; 
b
p< 0.05 versus 0 µM C8-CPPC (C8-CPPC effect) 
 
FIG.7. (A and B) Dihydroceramides impair adipocyte differentiation during early 
adipogenesis. 3T3L1 preadipocytes treated withC2-DhC (50µM) for a period of 48h at 
d0 or at d3 of differentiation. ORO staining and mRNA expression of adipogenesis and 
lipid metabolism genes. Mean ± Sem of two separated experiments performed in 
triplicate; *p< 0.05 vs. control. (C) Dihydroceramides decrease ligand-mediated PPARγ 
transactivation. Cells were treated with DMSO as a control group, Rosiglitazone 10uM,  
GW1929 10uM, C2 and C16 dihydroceramides and ceramides 100 uM as indicated. 
Graphs represent the average of 3 independent experiments.  p< 0.05.  (*) vs control 
cells, (#) vs Rosiglitazone and (&) vs GW1929. 
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Table1. Clinical characteristics of controls and morbidly obese 
patients  
 
1
 Values are means ± SEM. HDL-c= High density lipoprotein-cholesterol 
 
 
 Controls Morbidly obese 
Male/Female 3/3 14/14 
Age, years 52.17± 5.1 41.57 ± 2.96 
Weight, Kg 74.00 ± 0.71 155.5 ± 7.32 
Height, cm 162.60 ± 1.60 165.53 ± 2.49 
BMI, Kg/m2 25.04  ± 0.55 56.51 ± 1.68 
Serum insulin, UI/ml 11.23 ± 1.58 30.09 ± 2.30 
HOMA-IR 3.51 ± 0.48 8.18 ± 0.78 
Serum glucose, mmol/l 6.03 ± 0.32 5.74 ± 0.26 
Serum cholesterol, mmol/l 4.68 ± 0.40 4.92 ± 0.25 
HDL cholesterol, mmol/l 0.97 ± 0.23 1.10 ± 0.09 
Triglycerides, mmol/l 1.08 ± 0.20 1.42 ± 0.19  
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SUPPLEMENTAL FIG.1. mRNA expression levels of DEGS1 in stromal vascular 
fraction and adipocytes of different fat depots in wild type and ob/ob mice (n=3). 
p<0.05: (a) versus svf. (b) versus lean WT 
 
SUPPLEMENTAL FIG.2. (A) Expression levels of DEGS1 and other ceramide 
related enzymes in visceral adipose tissue of morbidly obese patients (B) Expression 
levels ceramide related genes in response to HFD intervention in rodents(C) Expression 
levels ceramide related genes in ob/ob mice. The panels show means ± SEM of 28 
morbidly obese patients and 6 lean controls for the human study and 6 to 8 animals per 
group in the rodent studies. Significant differences at p<0.05: (*) versus lean controls. 
 
SUPPLEMENTAL FIG.3.  (A) Positive correlation between the mRNA expression 
levels of PPARγ2 and DEGS1 in WT and DEGS1 3T3-L1 knockdown cells with or 
without Rosiglitazone (0.1 µM) at 9 days of adipocyte differentiation. The Spearman 
correlation coefficients were calculated to estimate the linear correlations between 
variables. The rejection level for a null hypothesis was p < 0.01 (B, C and D) mRNA 
DESG1 expression in white adipose tissue (WAT), skeletal muscle (SKM) and liver of 
wild-type, PPARγ2 KO and POKO (PPARγ2 -/- and lep -/-) mice.  Graphs show the 
mean ± SEM of a group of 6-8 animals.  *p< 0.05 versus wild-type mice.   
 
SUPPLEMENTAL FIG.4.  (A) Lipid accumulation in control and DEGS1 3T3-L1 
knockdown cells treated with Rosiglitazone (0.1 µM) after 9 days of adipocyte 
differentiation. Lipid content was analyzed using O Red Oil staining. Graph shows the 
mean ± SEM of two separate experiments performed in triplicate; *p< 0.05 versus 
control cells.  Panels show one representative experiment (B) mRNA expression of 
genes involved in adipocyte differentiation and lipid accumulation in controls and 
DEGS1 3T3-L1 knockdown cells with or without Rosiglitazone (0.1 µM) at day 9 of 
adipocyte differentiation. Graphs show the mean ± SEM of two separate experiments 
performed in triplicate; 
a
p< 0.05 versus WT untreated cells and 
b
p< 0.05 versus WT 
cells treated with Rosiglitazone. 
 
SUPPLEMENTAL FIG.5. (A and B) mRNA and protein expression of PPARγ2, 
cEBPα, several cyclins and cdk2 in control and DEGS1 knock-down cells during early 
adipogenesis (at 0, 24 and 48 hours after adipocyte differentiation induction). Panels 
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show one representative experiment of three different experiments performed 
separately. Graphs show the mean ± SEM of three separate experiments.  *p< 0.05 vs. 
control cells. Rosi, Rosiglitazone 
 
SUPPLEMENTAL FIG.6.  
A) Adipocyte mean area and B) frequency of distribution   of gonadal and  inguinal 
WAT adipocytes (1000-3000 per mouse, n=8) from vehicle and C8-CPPC treated mice. 
P < 0.05  
 
SUPPLEMENTAL FIG.7 
(A and B) mRNA expression levels of DEGS1, genes involved in differentiation 
(PPARγ1, PPARγ2 and cEBPα), lipid accumulation (LPL, FAS and CD36) and 
oxidative stress (Catalase, GXP1, GRS1, PRDx1, PRDx5, SOD1 and SOD2) in primary 
murine adipocytes treated with C8-CPPC for 20 hours. Panel shows the mean ± SEM of 
two separated experiments. *p< 0.05 versus untreated primary adipocytes.   
 
SUPPLEMENTAL FIG.8. Total dihydroceramide and ceramide levels in controls and  
mRNA expression of enzymes involved in ceramide synthesis pathways in control and 
DEGS1 knockdown cells at 0 (A) and 9 (B) days of differentiation. Graphs show the 
mean ± SEM of two separate experiments *p< 0.05 vs. control cells for gene expression 
and p< 0.00 for lipidomic analysis.   
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